Aurobindo Pharma gets tax demand of ₹13 crore, including interest and penalties

PTI Updated - May 03, 2024 at 05:35 PM.

Aurobindo Pharma Ltd. said on Friday it has received a tax demand of over ₹13 crore, including interest and penalty, from the GST authority over an ineligible input tax credit claim.

Also read: Aurobindo Pharma Q3 net up 17% at ₹836 crore

The Deputy Commissioner (ST) STU-1 of GST, Punjagutta Division, Hyderabad, Commercial Taxes Department, Telangana, has passed an order under relevant provisions of the Central Goods and Services Tax Act, 2017 and the TGST Act, 2017 for FY 2018-19 to this effect.

The order demanded the reversal of ITC and the payment of GST amounting to ₹6,54,50,645 along with interest of ₹5,92,20,900 and a penalty of ₹65,51,354, Aurobindo Pharma said in a regulatory filing.

It claims ineligible ITC and orders reversal of ITC, demanding GST along with interest, the company added.

The company intends to file an appeal before appellate authority, Aurobindo Pharma said, adding there is no material impact on its financials or operations due to the order.

Published on May 3, 2024 12:05

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

TheHindu Businessline operates by its editorial values to provide you quality journalism.

This is your last free article.